Cancer

Views & Analysis

In the last two years, the first PD-1 checkpoint inhibitor drugs to reach patients have launched a revolution in cancer care.

News

Israeli firm buys rights to near-copies of Roche blockbusters.

News

Collaboration focuses on cancer epigenetics.

Partner Content

Partner Content

The rush to discover the next big frontier in cancer medicine is more evident than it ever has been since the introduction of targeted therapies.

Partner Content

Partner Content

Ever more-specific cancer medicines carry the advantage of more personalised treatments for those with the disease.

News

Alecensa and Roactemra are breakthroughs, says FDA.